Home > Product > Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder
$0.00 (USD)

Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder

You can download the PDF by clicking here. If you would like one or more copies in print, but do not have the resources, please place an order above.

Gives an overview of data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Discusses the implications of utilizing medication-assisted treatment a a recovery support.


Publication Date: 2/2016
Format: Toolkit
Audience: Public Health Professionals, Policymakers, Professional Care Providers, Program Planners, Administrators, & Project Managers
Population Group: People with Substance Use Disorders
Publisher: SAMHSA
Series: SAMHSA Advisory
Downloadable: Yes, Click Here.